ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Metrics to compare | ABVC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABVCPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −1.1x | −0.7x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 0.7x | 2.4x | 2.6x | |
Price / LTM Sales | 12.1x | 13.9x | 3.2x | |
Upside (Analyst Target) | - | 102.4% | 46.6% | |
Fair Value Upside | Unlock | 33.4% | 7.4% | Unlock |